|
Asensio-Lopez M.d.C., Ruiz-Ballester M., Pascual-Oliver S., Bastida-Nicolas F.J., Sassi Y., Fuster J.J., Pascual-Figal D., Soler F., Lax A. AEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury. Molecular Medicine. December 2025. 31. 10.1186/s10020-025-01242-1
AÑO: 2025; IF: 6.4
|
|
Lax A., Soler F., Fernandez del Palacio M.J., Pascual-Oliver S., Ballester M.R., Fuster J.J., Pascual-Figal D., Asensio-Lopez M.d.C. Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis. Molecular Therapy Nucleic Acids. 13 June 2023. 32:704-720. 10.1016/j.omtn.2023.04.031
AÑO: 2023; IF: 6.5
|
|
Soler F., Lax A., Carmen Asensio M., Pascual-Figal D., Fernández-Belda F. Passive Ca<sup>2+</sup> overload in H9c2 cardiac myoblasts: Assessment of cellular damage and cytosolic Ca<sup>2+</sup> transients. Archives of Biochemistry and Biophysics. 15 August 2011. 512:175-182. 10.1016/j.abb.2011.05.019
AÑO: 2011; IF: 2.935
|
|
Asensio Lopez MDC, Ruiz Ballester M, Bastida Nicolas FJ, Soler Pardo F, Alonso-Romero JL, Caro-Martinez C, Pascual Figal D, Lax A. miR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation. Int J Mol Sci. 2025 Oct 14;26(20):10002. doi: 10.3390/ijms262010002. PubMed PMID: 41155295; PubMed Central PMCID: PMC12562630.
AÑO: 2025; IF: 4.9
|
|
Asensio-Lopez MDC, Severino P, Lax A. Editorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings. Front Pharmacol. 2025 Apr 28;16:1607362. doi: 10.3389/fphar.2025.1607362. eCollection 2025. No abstract available. PubMed PMID: 40356986; PubMed Central PMCID: PMC12067795.
AÑO: 2025; IF: 4.8
|